 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...2930313233343536373839...4142» |
- | Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Impact of Estradiol Addback (clinicaltrials.gov) - Aug 30, 2017
P1, N=60, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jun 2017 --> Sep 2016
- Ostarine (enobosarm) / Veru Inc
New P1 trial: Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density (clinicaltrials.gov) - Aug 29, 2017
P1, N=10, Recruiting, Sponsor: Havah Therapeutics Pty Ltd
- ||| Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Enrollment closed, Trial primary completion date, Metastases: CHEOPS: Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. (clinicaltrials.gov) - Aug 24, 2017
P2, N=120, Active, not recruiting, Sponsor: ARCAGY/ GINECO GROUP
Trial primary completion date: Jun 2017 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Jan 2018
- ||| anastrozole / Generic mfg., fulvestrant / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer (clinicaltrials.gov) - Aug 11, 2017
P2, N=72, Active, not recruiting, Sponsor: Mothaffar Rimawi
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Jan 2018 Recruiting --> Active, not recruiting | N=112 --> 72 | Trial primary completion date: Jul 2017 --> Oct 2016
- | Soltamox (tamoxifen citrate) / Jazz
New P4 trial: Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer (clinicaltrials.gov) - Aug 2, 2017
P4, N=600, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- | Trial primary completion date, Surgery: Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery (clinicaltrials.gov) - Aug 1, 2017
P3, N=3697, Active, not recruiting, Sponsor: Gruppo Italiano Mammella (GIM)
Recruiting --> Active, not recruiting | N=112 --> 72 | Trial primary completion date: Jul 2017 --> Oct 2016 Trial primary completion date: Mar 2016 --> Jul 2018
- | Ibrance (palbociclib) / Pfizer
Trial completion, Trial primary completion date, Combination therapy, Monotherapy, Metastases: TREnd: To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy (clinicaltrials.gov) - Aug 1, 2017
P2, N=115, Completed, Sponsor: Fondazione Sandro Pitigliani
Trial primary completion date: Mar 2016 --> Jul 2018 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Feb 2017
- | anastrozole / Generic mfg.
New P2 trial: PHANTOM: Pulmonary Hypertension and Anastrozole Trial (clinicaltrials.gov) - Jul 24, 2017
P2, N=84, Not yet recruiting, Sponsor: University of Pennsylvania
- | saracatinib (AZD0530) / AstraZeneca
Trial primary completion date: A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Jul 21, 2017
P2, N=59, Active, not recruiting, Sponsor: Joyce Marie Slingerland
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Feb 2017 Trial primary completion date: Jun 2017 --> Dec 2017
- ||||| Ibrance (palbociclib) / Pfizer
New P4 trial, HEOR, Patient reported outcomes, Metastases: PRECYCLE: Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (clinicaltrials.gov) - Jul 18, 2017
P4, N=960, Not yet recruiting, Sponsor: Palleos Healthcare GmbH
- | Soltamox (tamoxifen citrate) / Jazz
New P2 trial, IO biomarker: PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov) - Jul 16, 2017
P2, N=39, Not yet recruiting, Sponsor: Medical College of Wisconsin
- || miransertib (MK-7075) / Merck (MSD)
Trial primary completion date, Combination therapy: Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole (clinicaltrials.gov) - Jul 13, 2017
P1b, N=52, Recruiting, Sponsor: ArQule
Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Jun 2017 --> Dec 2017
- everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Jul 11, 2017
P2, N=48, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Jun 2017 --> Sep 2017
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Jul 11, 2017
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jun 2017 --> Sep 2017 Trial primary completion date: Dec 2018 --> Dec 2019
- | anastrozole / Generic mfg., tamoxifen / Generic mfg.
New P2 trial: The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers (clinicaltrials.gov) - Jul 7, 2017
P2, N=82, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- | anastrozole / Generic mfg., tamoxifen / Generic mfg.
Enrollment closed, Trial primary completion date: DATA: Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer (clinicaltrials.gov) - Jun 28, 2017
P3, N=1914, Active, not recruiting, Sponsor: Maastricht University Medical Center
Trial primary completion date: Dec 2018 --> Dec 2019 Completed --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Apr 2022
- | Ibrance (palbociclib) / Pfizer
Enrollment change, Combination therapy: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - Jun 27, 2017
P2, N=87, Recruiting, Sponsor: Washington University School of Medicine
Completed --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Apr 2022 N=55 --> 87
- | anastrozole / Generic mfg., bicalutamide / Generic mfg.
Enrollment change, Combination therapy: BATT: Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis] (clinicaltrials.gov) - Jun 16, 2017
P2, N=14, Active, not recruiting, Sponsor: AstraZeneca
N=55 --> 87 N=21 --> 14
- | denifanstat (TVB-2640) / Sagimet Biosci
New P2 trial: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jun 7, 2017
P2, N=80, Not yet recruiting, Sponsor: Mayo Clinic
- | anastrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: LATTE: Long-term Anastrozole Versus Tamoxifen Treatment Effects (clinicaltrials.gov) - Jun 2, 2017
P=N/A, N=78, Completed, Sponsor: American Cancer Society, Inc.
N=21 --> 14 Enrolling by invitation --> Completed | N=4337 --> 78 | Trial primary completion date: Sep 2015 --> May 2017
- | capecitabine / Generic mfg.
Trial initiation date, Trial primary completion date, Metastases: MECCA: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (clinicaltrials.gov) - Jun 1, 2017
P3, N=240, Not yet recruiting, Sponsor: Sun Yat-sen University
Enrolling by invitation --> Completed | N=4337 --> 78 | Trial primary completion date: Sep 2015 --> May 2017 Initiation date: Jun 2016 --> Sep 2017 | Trial primary completion date: May 2019 --> May 2021
- |||||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - May 31, 2017
P3, N=496, Recruiting, Sponsor: Alliance Foundation Trials, LLC.
Initiation date: Jun 2016 --> Sep 2017 | Trial primary completion date: May 2019 --> May 2021 Not yet recruiting --> Recruiting | Initiation date: Feb 2017 --> Jun 2017
- | anastrozole / Generic mfg., fulvestrant / Generic mfg.
Enrollment change: ALTERNATE: Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - May 18, 2017
P3, N=1455, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting | Initiation date: Feb 2017 --> Jun 2017 N=2820 --> 1455
- |||| Verzenio (abemaciclib) / Eli Lilly
Trial completion, Enrollment change, Combination therapy, Monotherapy: neoMONARCH: A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - May 18, 2017
P2, N=224, Completed, Sponsor: Eli Lilly and Company
N=2820 --> 1455 Active, not recruiting --> Completed | N=148 --> 224
- ||| xentuzumab (BI-836845) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (clinicaltrials.gov) - May 18, 2017
P1, N=90, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | N=148 --> 224 Not yet recruiting --> Recruiting
- |||| Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date, Metastases: MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - May 3, 2017
P3, N=450, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2017 --> Jan 2017
- || Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - May 2, 2017
P4, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2017 --> Jan 2017 Trial primary completion date: Dec 2016 --> Jul 2017
- | Enrollment closed, Trial primary completion date: FLAG: Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women (clinicaltrials.gov) - May 1, 2017
P2, N=147, Active, not recruiting, Sponsor: Samsung Medical Center
Trial primary completion date: Dec 2016 --> Jul 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jun 2018
- | MK-2206 / Merck (MSD)
Enrollment change, Combination therapy: Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Apr 25, 2017
P2, N=16, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jun 2018 N=87 --> 16
- |||||| Ibrance (palbociclib) / Pfizer
Biomarker, Enrollment open, Combination therapy, Circulating tumor DNA, Metastases: PADA-1: PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection (clinicaltrials.gov) - Apr 20, 2017
P3, N=800, Recruiting, Sponsor: UNICANCER
N=87 --> 16 Not yet recruiting --> Recruiting
- | goserelin acetate / Generic mfg., anastrozole / Generic mfg.
Phase classification, Trial termination, Trial primary completion date: Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome (clinicaltrials.gov) - Apr 18, 2017
P1, N=66, Terminated, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P1 | Recruiting --> Terminated | Trial primary completion date: Sep 2010 --> Feb 2010; PI relocated
- | Ibrance (palbociclib) / Pfizer
Trial primary completion date, Combination therapy: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - Apr 14, 2017
P2, N=55, Recruiting, Sponsor: Washington University School of Medicine
Phase classification: P=N/A --> P1 | Recruiting --> Terminated | Trial primary completion date: Sep 2010 --> Feb 2010; PI relocated Trial primary completion date: Mar 2017 --> Dec 2020
- ||| Ibrance (palbociclib) / Pfizer
Enrollment change, Trial primary completion date, Metastases: INGE-B: Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (clinicaltrials.gov) - Apr 13, 2017
P2, N=360, Recruiting, Sponsor: iOMEDICO AG
Trial primary completion date: Mar 2017 --> Dec 2020 N=120 --> 360 | Trial primary completion date: Sep 2021 --> Jun 2019
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Apr 7, 2017
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
N=120 --> 360 | Trial primary completion date: Sep 2021 --> Jun 2019 Trial primary completion date: May 2017 --> Dec 2018
- ||| fexagratinib (ABSK091) / Abbisko
Enrollment closed, Trial primary completion date, Combination therapy: AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL) (clinicaltrials.gov) - Apr 7, 2017
P2a, N=56, Active, not recruiting, Sponsor: Imperial College London
Trial primary completion date: May 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Nov 2016
- ||||| Kisqali (ribociclib) / Novartis
Enrollment closed, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Apr 6, 2017
P3, N=672, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Nov 2016 Recruiting --> Active, not recruiting
- | anastrozole / Generic mfg., tamoxifen / Generic mfg.
Trial primary completion date: IBIS-II DCIS: Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ (clinicaltrials.gov) - Apr 4, 2017
P3, N=2980, Active, not recruiting, Sponsor: Queen Mary University of London
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Dec 2015
- ||| xentuzumab (BI-836845) / Boehringer Ingelheim
New P1 trial, Combination therapy, Metastases: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (clinicaltrials.gov) - Apr 4, 2017
P1, N=90, Not yet recruiting, Sponsor: Boehringer Ingelheim
- pazopanib / Generic mfg., anastrozole / Generic mfg.
Trial termination: Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer (clinicaltrials.gov) - Mar 31, 2017
P2, N=2, Terminated, Sponsor: University of Arizona
Trial primary completion date: Feb 2017 --> Dec 2015 Completed --> Terminated; Slow accrual
- || Enrollment closed, Trial primary completion date, IO biomarker, Metastases: Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=175, Active, not recruiting, Sponsor: VU University Medical Center
Completed --> Terminated; Slow accrual Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Sep 2017
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Mar 27, 2017
P3, N=660, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Sep 2017 Active, not recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: BOOSTER: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Mar 8, 2017
P2, N=160, Active, not recruiting, Sponsor: Japan Breast Cancer Research Group
Active, not recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- | Verzenio (abemaciclib) / Eli Lilly
Phase classification, Metastases: KEYNOTE 287: A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer (clinicaltrials.gov) - Feb 13, 2017
P1b, N=75, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jun 2017 --> Jun 2018 Phase classification: P2 --> P1b
- |||| Zokinvy (lonafarnib) / Eiger
Trial completion, Metastases: Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480) (clinicaltrials.gov) - Feb 6, 2017
P2, N=110, Completed, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P2 --> P1b Active, not recruiting --> Completed
- saracatinib (AZD0530) / AstraZeneca
Enrollment closed: A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Jan 26, 2017
P2, N=59, Active, not recruiting, Sponsor: Joyce Marie Slingerland
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | anastrozole / Generic mfg.
Enrollment closed: STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing) (clinicaltrials.gov) - Jan 24, 2017
P3, N=2023, Active, not recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment open: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - Jan 19, 2017
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- megestrol / Generic mfg.
New P2 trial, Metastases: MEGA: A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Jan 19, 2017
P2, N=20, Not yet recruiting, Sponsor: Instituto Nacional de Cancer, Brazil
- Trial primary completion date: Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients (clinicaltrials.gov) - Jan 14, 2017
P3, N=104, Recruiting, Sponsor: Dharmais National Cancer Center Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Mar 2017
- |||| Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date, Metastases: MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Jan 10, 2017
P3, N=450, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Jun 2017 --> Nov 2017